Cargando…
Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation
SIMPLE SUMMARY: In 2021, the identification of effective biomarkers became a major focus of prostate cancer (PCa) in order to improve outcomes and select potentially responsive patients. The aim of this contribution is to review the main 2021 novelties in prognostic and therapeutic markers in PCa, w...
Autores principales: | Cimadamore, Alessia, Mazzucchelli, Roberta, Lopez-Beltran, Antonio, Massari, Francesco, Santoni, Matteo, Scarpelli, Marina, Cheng, Liang, Montironi, Rodolfo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307279/ https://www.ncbi.nlm.nih.gov/pubmed/34298683 http://dx.doi.org/10.3390/cancers13143471 |
Ejemplares similares
-
Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?
por: Montironi, Rodolfo, et al.
Publicado: (2021) -
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
por: Aurilio, Gaetano, et al.
Publicado: (2020) -
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians
por: Gasparrini, Silvia, et al.
Publicado: (2019) -
Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression
por: Cimadamore, Alessia, et al.
Publicado: (2017) -
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
por: Montironi, Rodolfo, et al.
Publicado: (2020)